Twist Bioscience Co. (NASDAQ:TWST) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Twist Bioscience Co. (NASDAQ:TWST) have been assigned an average rating of “Moderate Buy” from the ten analysts that are presently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $51.90.

Several equities analysts have recently commented on TWST shares. Wolfe Research began coverage on shares of Twist Bioscience in a research report on Friday, December 13th. They issued an “outperform” rating and a $60.00 target price for the company. TD Cowen restated a “buy” rating and set a $58.00 target price on shares of Twist Bioscience in a research note on Tuesday, November 26th. Robert W. Baird raised their target price on Twist Bioscience from $46.00 to $48.00 and gave the company an “outperform” rating in a report on Tuesday, November 19th. Scotiabank upped their price objective on Twist Bioscience from $50.00 to $54.00 and gave the stock a “sector outperform” rating in a research report on Tuesday, November 19th. Finally, Evercore ISI lifted their target price on Twist Bioscience from $52.00 to $56.00 and gave the company an “outperform” rating in a research report on Tuesday, October 1st.

Insider Activity

In related news, SVP Paula Green sold 3,310 shares of the business’s stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $43.21, for a total value of $143,025.10. Following the sale, the senior vice president now owns 84,585 shares of the company’s stock, valued at $3,654,917.85. The trade was a 3.77 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Adam Laponis sold 856 shares of the firm’s stock in a transaction on Wednesday, October 9th. The stock was sold at an average price of $41.81, for a total value of $35,789.36. Following the transaction, the chief financial officer now directly owns 73,397 shares of the company’s stock, valued at approximately $3,068,728.57. This represents a 1.15 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 99,659 shares of company stock valued at $4,484,602 over the last quarter. 3.92% of the stock is owned by company insiders.

Institutional Trading of Twist Bioscience

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. CWM LLC boosted its stake in shares of Twist Bioscience by 27.4% in the 2nd quarter. CWM LLC now owns 2,437 shares of the company’s stock valued at $120,000 after purchasing an additional 524 shares during the last quarter. Blue Trust Inc. grew its holdings in Twist Bioscience by 2,912.8% during the 2nd quarter. Blue Trust Inc. now owns 1,175 shares of the company’s stock worth $58,000 after acquiring an additional 1,136 shares during the period. Nisa Investment Advisors LLC raised its position in shares of Twist Bioscience by 31.3% in the 2nd quarter. Nisa Investment Advisors LLC now owns 2,288 shares of the company’s stock worth $113,000 after acquiring an additional 546 shares in the last quarter. EdgeRock Capital LLC acquired a new position in shares of Twist Bioscience in the 2nd quarter valued at about $43,000. Finally, Calamos Advisors LLC acquired a new position in shares of Twist Bioscience in the 2nd quarter valued at about $281,000.

Twist Bioscience Stock Performance

TWST opened at $47.94 on Friday. The firm has a market cap of $2.85 billion, a P/E ratio of -13.32 and a beta of 1.82. The business’s fifty day moving average is $45.28 and its 200-day moving average is $46.77. Twist Bioscience has a 52-week low of $27.41 and a 52-week high of $60.90.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.